Nkarta, Inc. (NASDAQ:NKTX) Short Interest Update

Nkarta, Inc. (NASDAQ:NKTX) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totaling 6,020,166 shares, a decrease of 44.5% from the December 15th total of 10,850,709 shares. Based on an average daily trading volume, of 669,661 shares, the days-to-cover ratio is presently 9.0 days. Approximately 9.3% of the shares of the stock are short sold. Approximately 9.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 669,661 shares, the days-to-cover ratio is presently 9.0 days.

Institutional Trading of Nkarta

Several institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in Nkarta by 478.4% during the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after purchasing an additional 57,399 shares during the period. AQR Capital Management LLC grew its position in shares of Nkarta by 300.5% during the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after buying an additional 504,272 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock worth $1,253,000 after buying an additional 80,211 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after buying an additional 852,559 shares during the period. Finally, CWM LLC increased its stake in shares of Nkarta by 23.4% during the second quarter. CWM LLC now owns 34,758 shares of the company’s stock worth $58,000 after buying an additional 6,601 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Stifel Nicolaus decreased their target price on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Nkarta Stock Performance

Shares of Nkarta stock traded down $0.11 during trading hours on Thursday, hitting $1.96. The company’s stock had a trading volume of 955,292 shares, compared to its average volume of 820,458. The stock has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.60. Nkarta has a twelve month low of $1.31 and a twelve month high of $2.74. The firm has a fifty day moving average of $1.87 and a 200-day moving average of $2.02.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. On average, sell-side analysts expect that Nkarta will post -1.7 earnings per share for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.